Glycoprotein Sialylation via Precursor Supplementation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing recombinant glycoproteins struggle to achieve optimal sialylation levels, leading to reduced bioactivity, stability, and increased side effects, as existing systems fail to replicate human glycosylation patterns effectively, and prior art lacks suitable tests and production systems to correlate sialylation degree with biological activity.
Innovation Solution
A process involving expression of glycoproteins in cell lines with defects in the sugar nucleotide biosynthetic pathway of sialic acids, supplemented with sialic acid precursors, to achieve differential sialylation forms, with activity determination through bioassays, allowing selection of the most active form and optimal precursor concentration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional production systems (CHO cells, bacteria, yeast) are used to produce recombinant glycoproteins, then protein production is achieved, but the glycosylation pattern differs from human glycosylation and sialylation is suboptimal
Solution Approach 1:
The patent modifies the glycosylation parameters by changing the cellular environment and metabolic conditions of the host cells. Specifically, it uses CHO cells with defined glycosylation enzyme deficiencies and supplements them with specific sugar nucleotide precursors (CMP-sialic acid, UDP-galactose, UDP-N-acetylglucosamine) to achieve human-like glycosylation patterns with optimized sialylation, resolving the contradiction between manufacturing precision and ease of manufacture.
Solution Approach 2:
The patent introduces sugar nucleotide precursors as intermediary substances that mediate the glycosylation process. These precursors (CMP-sialic acid, UDP-galactose, UDP-N-acetylglucosamine) serve as building blocks that enable the host cells to synthesize human-type glycan structures, bridging the gap between conventional production systems and desired human glycosylation patterns.
2Duration of action of moving object
If sialylation degree is increased to maximize serum half-life, then bioavailability is improved, but biological activity may be compromised and production complexity increases
Solution Approach 1:
The patent optimizes the sialylation parameter by controlling the concentration and type of sialic acid precursors provided to the host cells. By adjusting these parameters, the system achieves optimal sialylation levels that simultaneously extend serum half-life and maintain biological activity, avoiding the trade-off between these two properties.
Solution Approach 2:
The patent employs feedback mechanisms to monitor and adjust sialylation levels. Through characterization of the glycoprotein products and analysis of their biological activity, the system identifies optimal sialylation degrees that balance extended half-life with maintained efficacy, allowing for iterative optimization of the production process.
3Duration of action of moving object
If PEGylation is applied to extend serum half-life, then bioavailability is improved, but protein activity decreases and production steps increase
Solution Approach 1:
The patent performs glycosylation optimization during the protein production phase itself, rather than applying extensions like PEGylation after production. By pre-optimizing the glycan structure and sialylation levels in the host cells during expression, the system achieves extended half-life through intrinsic glycosylation properties, eliminating the need for subsequent PEGylation steps and reducing overall process complexity.
4Reliability
If conventional glycoproteins are produced without optimized sialylation, then production is simpler, but bioactivity is reduced and side effects increase
Solution Approach 1:
The patent modifies the metabolic parameters of the host cells by supplementing with specific sugar nucleotide precursors. This changes the glycosylation output to achieve human-like patterns with optimized sialylation, thereby improving biological activity and reducing side effects while maintaining production simplicity through a relatively straightforward supplementation approach.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in highly active glycoproteins with optimized sialylation, enhancing bioactivity, stability, and reducing side effects, enabling improved therapeutic efficacy and bioavailability.
Implementation Method 1
The invention relates to highly active glycoproteins with optimized sialylation degrees... expression of glycoproteins in cell lines with defects in the sugar nucleotide biosynthetic pathway of sialic acids, supplemented with sialic acid precursors, to achieve differential sialylation forms
Data Source
AI summary
The present invention relates to highly active glycoproteins with specific sialylation degrees, a pharmaceutical composition for use in diagnosis or therapy comprising the glycoproteins, a method for the determination of highly active glycoproteins and of the conditions for their production, a method for producing the highly active glycoproteins, and a method for differential sialylation of secretory glycoproteins. The invention also relates to the use of the recombinantly expressed highly active glycoproteins for biological purposes and for prophylactic and/or therapeutic treatment or diagnosis of diseases, particularly bone marrow transplantation, neutropenia, cytopenia, AML and myelodysplastic syndromes, cancer, HIV and/or diseases of hematopoietic systems.